Zogenix — Investor Presentation (June 2014)
31 slides from Zogenix's investor presentation, Jun 23, 2014
Slide 1: Overview
Exhibit 99.1 Overview June 2014
Slide 2: Forward Looking Statement
Forward Looking Statement Zogenixcautionsyou that statementsincludedin this presentationthat are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming,""des
Slide 3: The Zogenix Opportunity
The Zogenix Opportunity UNIQUE MODEL Combining Medicine and Technology to Provide Differentiated Products That Meet Medical Needs PROVEN EXECUTION 2 FDA Approvals, Successful Commercial Product, Validated DosePro Platform, Strong Pipeline SIGNIFICANT MARKET OPPORTUNITY 1st to Market in Large Opportu
Slide 4: Unique Model: Combining Medicine and Technology
Unique Model: Combining Medicine and Technology COMMERCIALIZING andDEVELOPING InnovativeProducts Medicine CHRONIC PAIN ANTIPSYCHOTIC INTERNAL/EXTERNAL Hydrocodone Development Without Risperidone Opportunities Acetaminophen Oral, 12-Hour Once Monthly DosePro® Needle-Free Extended Release Subcutaneous
Slide 5: 1st to Develop/Market
1st to Develop/Market 1 st Oral, 12-Hour 1 st Subcutaneous 1 st DosePro Needle Free Extended Release Once-Monthly Product For Acute Hydrocodone without Antipsychotic Migraines And Cluster Acetaminophen Headaches $16B Market $29B+ Market* $105M Transaction US Market Unpartnered Worldwide Market Right
Slide 6: SUMAVEL DosePro Transaction
SUMAVEL DosePro® Transaction • Better Call Point Fit • Strengthens Balance Sheet: $85M* in • Significant Resources for Education Cash, $20M in Milestone Payments and Marketing • Ownership of DosePro® Needle-Free • Transfer of New Drug Application Delivery System Technology • Worldwide Product Rights
Slide 7: Strong Pipeline
Strong Pipeline PRODUCT/ PROGRAM Pre-Clinical Phase 1 Phase 2 Phase 3 NDA Commercial Status ZOHYDRO® ER Approved October 25 ER Hydrocodone Capsules 2013 For Chronic Pain Launched March 3rd 2014 2 AD Formulations N/A N/A • Targeting Late 2016 TM RELDAY Monthly SQ Risperidone • MD PK Study in 2H for S
Slide 8: First Acetaminophen-Free Hydrocodone Product
1 st Oral, Extended Release Hydrocodone 1 st Acetaminophen-Free Hydrocodone Product FDA Approved Launched October 2013 March 2014 8
Slide 9: ZOHYDRO ER Progress
ZOHYDRO ER Progress • 1,141 Prescriptions in First Quarter 2014 MOMENTUM • 8,935 Prescriptions from Launch Through June 13, (1) 2014 • >85% of Prescriptions for ZOHYDRO ER are for the 30 mg Strength or Less, as Anticipated EDUCATION/ • Engaging Local, State and National Officials to Educate on LEGAL
Slide 10: ZOHYDRO ER Clinicians and Patients
ZOHYDRO ER CLINICIANS PATIENTS • Prescribethe RIGHT • Consistent12-Hour Doseof Hydrocodone Delivery • SimplifiesConversion • LessFrequentDosing from Immediate Release(IR)to • ReducedRiskof ExtendedRelease(ER) AcetaminophenToxicity • NewOptionfor Opioid • Hydrocodone: Rotation EstablishedTolerability
Slide 11: Ideal Profile for Chronic Pain Treatment
Ideal Profile for Chronic Pain Treatment ZOHYDRO ER vs. Vicodin Vicodin 10 mg T0 + T6 Zohydro ER 20 mg T0 Mean Plasma Concentration ng/ml Time (Hours) CONSISTENT LOWER LESS 12 Hour Profile to Prevent Maximum Peak to Trough Breakthrough Pain Concentration Variation 11
Slide 12: Responder Graph and Indication Details
Responder Graph and Indication Details Responders % Responding Subjects ZOHYDRO ERis an OpioidAgonist,Extended-Release OralFormulationof HydrocodoneWithout Acetaminophen,for the Managementof PainSevereEnoughto RequireDaily,Around-the-Clock, Long-TermOpioid Treatmentand for WhichAlternativeTreatmentO
Slide 13: Lower Liver Toxicity
Lower Liver Toxicity FACT ZOHYDRO ER Is the First and Only Extended-Release Hydrocodone Pain Product without Acetaminophen Acetaminophen Is the Acetaminophen Overdose 63Percentof Unintentional Leading Cause of Severe AlsoIsa LeadingCauseof AcetaminophenOverdoses Liver Failure in This AcuteLiverFailu
Slide 14: The Market Need for Extended Release (ER) Hydrocodone
The Market Need for Extended Release (ER) Hydrocodone 13 Million ER Opioid TRx Annually 6.6M 1stER 5.0M Hydrocodone 1.0M 0.2M Avinza, Kadian, Opana ER ER Embeda, MS OxyContin (Including Exalgo Products Contin+ Generics) Generic ERs ER Sales $2.6B $1.4B $528M $238M Source:SHSSource®TRxand retail doll
Slide 15: The Medical Need
The Medical Need 47 Million* Patients Take 5% IR HC/APAP Take It for Chronic Pain >90 Days 2.4 Million > 20mg HC/d1 Patients Meeting the Need in Opioid Rotation * FDAanalysisof IMSHealthTotal PatientTrackerdata for 2011(presentedat ZohydroERAdvisoryCommittee,December2012) 1 Proportionof chronicusepa
Slide 16: ZOHYDRO ER Illustrative 5% Market Opportunity
ZOHYDROo ER Illustrative 5% Market Opportunity 2.4 Million Patients 5%Penetration(120,000Patients) WACPriceper Dayof Therapy:$8.30 Daysper Month of Therapy:30 # of TRxper Year:8 Approximately $240 Million Gross Revenue 16
Slide 17: Systematic Approach to Responsible Commercialization
Systematic Approach to Responsible Commercialization STORAGE • Distributionof SafeStorageMechanisms MONITORING • Surveillanceand Monitoring to Detect PotentialMisuse,Abuseand Diversion SALES • Certificationof ZogenixTerritory Representatives • IncentiveCompensationBasedExclusivelyOnAchieving SafeUse
Slide 18: Multiple Educational Resources for Patients, Prescribers, and Pharmacists
Multiple Educational Resources for Patients, Prescribers, and Pharmacists Patient Toolkit Education and Safe Storage Offers HCP Kit Conversion Healthcare Guide and Provider Websites 18
Slide 19: Successful Execution: ZOHYDRO ER
Successful Execution: ZOHYDRO ER Commercial Organization of 190 Employees Responsibly Building Adoption for Long-Term Success FOCUS COMMITMENT COMPLIANCE CONTROL Targeting a Significant Footprint High Decile ER/LA 20,000 Opioid Prescribers 60% of EROpioidMarket (Top 6 Deciles) 19
Slide 20: Committed to Developing Abuse Deterrent (AD) Formulations
Committed to Developing Abuse Deterrent (AD) Formulations Modification of • First Step in AD ZOHYDRO ER Existing SODAS • Addition of Inert Beads That Form a Viscous Gel Formulation When Crushed and Dissolved in Aqueous Solvents with Alkermes • Insufflation and Injection Resistant TWO Simultaneous AP
Slide 21: Once-Monthly Risperidone
1 st Once-Monthly Risperidone With A Unique PK Profile, Available as a Subcutaneous Injection for Treatment of Schizophrenia Phase 1 Proof of Concept Established 21
Slide 22: Long Acting Injections (LAIs): A Highly Attractive Market
Long Acting Injections (LAIs): A Highly Attractive Market Further Clinical Evidence of Earlier LAI Usage Will Likely Drive Additional Upside U.S. LAI Sales (Schizophrenia) $2.8 Billion Market $ Millions in U.S.+ Europe in 2013 • Highly Concentrated U.S. Market with $1.2B 11,000 Psychiatrists Prescri
Slide 23: RELDAY Surpasses Current LAI Atypical Antipsychotics on Multiple Attributes
RELDAY Surpasses Current LAI Atypical Antipsychotics (AA) on Multiple Attributes KEY ATTRIBUTES RISPERDAL INVEGA ZYPREXA ABILIFY FROM PHYSICIAN CONSTA SUSTENNA RELPREVV MAINTENA RELDAY RESEARCH (RISPERIDONE) (PALIPERIDONE) (OLANZAPINE) (ARIPIPRAZOLE) (RISPERIDONE) Therapeutic Levels on Day 1 × × × ×
Slide 24: RELDAY: A Differentiated Product Profile vs. Available LAIs
RELDAY: A Differentiated Product Profile vs. Available LAIs Positive Physician Reaction Higher Relative Rating Initial Reaction to Relday Relative Rating of Clinical PARTICIPANT RATING OF RELDAY PROFILE and Product Merit 7 POINT SCALE: 1 = “WORST” AND 7 = “BEST” Average RELDAY 4.5 5.7 5.1 Risperdal®
Slide 25: RELDAY Clinical Program Status
RELDAY Clinical Program Status US PATHWAY STRATEGY • 505(b)(2) NDA Pathway Strategy in USA PROOF OF • Established in the First IND Study CONCEPT • Subjects with Schizophrenia (n=40) • Pharmacokinetics (PK) – Therapeutic Levels within 8 hours of Dosing – First Day Levels Consistent with Comparable Or
Slide 26: RELDAY Clinical Study Design
RELDAY Clinical Study Design OVERVIEW • Open-Label, PK and Safety, in Patients with Chronic, Stable Schizophrenia or Schizoaffective Disorder • Patients Randomizedinto One of FourCohorts: – Cohort 1: 60 mg Relday (0.5 mL SQ depot injection) – Cohort 2: 90 mg Relday (0.75 mL SQ depot injection) – Coh
Slide 27: Financial Highlights
Financial Highlights Q1 2014 Net Product Revenue (Unaudited Sumavel DosePro/service revenue~$7.4m, $7.7M Zohydro $286k) Market Capitalization $271M (6-20-14 ~139,539,151 Shares) Cash Balance (1) ~$100M (Q1 2014 proforma for sale of Sumavel DosePro to Endo) Debt/Royalty $0M (5-16-2014) Common Stock O
Slide 28: 2014 Financial Guidance
2014 Financial Guidance ZOHYDRO ER Revenue No Guidance in Launch Year Revenue for Manufacturing Low Single Digit Markup to Costs Which Will Be and Supply of Sumavel Recorded as a Component of Cost of Goods Sold DosePro for Endo ZOHYDRO ER Gross Margin*Approximately 85% of Net ZOHYDRO ER Revenue (Man
Slide 29: Experienced Management Team
Experienced Management Team INDUSTRY EXPERIENCE Roger Hawley* 27 Glaxo, GSK, Elan, InterMune Chief Executive Officer Stephen Farr, Ph.D.* 21 Aradigm, Cardiff University President Ann Rhoads 20 Premier, Sprout, DLJ, Bain & Co, Merrill Lynch Chief Financial Officer R. Scott Shively 32 Pfizer, Alpharma
Slide 30: Zogenix: Where Medicine Meets Technology
Zogenix: Where Medicine Meets Technology SIGNIFICANT MARKETS PROVEN RESPONSIBLE EXECUTION COMMERCIALIZATION UNIQUE INFRASTRUCTURE MODEL IN PLACE DEVELOPING andCOMMERCIALIZING InnovativeProducts CHRONIC PAIN ANTIPSYCHOTIC INTERNAL/EXTERNAL DosePro® Needle-Free Delivery Platform 1 st 1 st 1 st 30
Slide 31: ZOQCIIX” = A
NASDAQ: ZGNX ZOQCIIX” = A